{"id":3928,"date":"2019-03-21T11:43:15","date_gmt":"2019-03-21T11:43:15","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/poster\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\/"},"modified":"2025-12-12T11:35:58","modified_gmt":"2025-12-12T11:35:58","slug":"structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2","status":"publish","type":"poster","link":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\/","title":{"rendered":"Advancing Novel Fragment Hits for Epigenetic Target BRD3: A Structural Approach"},"content":{"rendered":"

Fragment-based drug discovery (FBDD) is a successful approach to hit finding in modern drug discovery and is proving particularly valuable for bromodomain-containing proteins, an emerging family of epigenetic regulators with potential as drug targets. We applied our integrated FBDD platform to the discovery of compounds targeting bromodomain-containing protein 3 (BRD3). Belonging to the bromodomain and extra-terminal motif (BET) family, BRD3 functions by binding acetylated lysine residues on chromatin and transcriptional regulators and is implicated in several disease phenotypes, including prostate cancer, medulloblastoma and NUT midline carcinoma.<\/p>\n","protected":false},"excerpt":{"rendered":"

Discover compounds targeting BRD3 with Fragment-Based Drug Discovery (FBDD) – a promising approach for drug development in epigenetics.<\/p>\n","protected":false},"featured_media":2559,"template":"","category":[1],"class_list":["post-3928","poster","type-poster","status-publish","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"yoast_head":"\nAdvancing Novel Fragment Hits for Epigenetic Target BRD3<\/title>\n<meta name=\"description\" content=\"Discover compounds targeting BRD3 with Fragment-Based Drug Discovery (FBDD) - a promising approach for drug development in epigenetics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Advancing Novel Fragment Hits for Epigenetic Target BRD3\" \/>\n<meta property=\"og:description\" content=\"Discover compounds targeting BRD3 with Fragment-Based Drug Discovery (FBDD) - a promising approach for drug development in epigenetics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-12T11:35:58+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Fragment-hits-for-BRD3-poster_-724x1024.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"724\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\\\/\",\"name\":\"Advancing Novel Fragment Hits for Epigenetic Target BRD3\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Fragment-hits-for-BRD3-poster_-scaled.jpg\",\"datePublished\":\"2019-03-21T11:43:15+00:00\",\"dateModified\":\"2025-12-12T11:35:58+00:00\",\"description\":\"Discover compounds targeting BRD3 with Fragment-Based Drug Discovery (FBDD) - a promising approach for drug development in epigenetics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Fragment-hits-for-BRD3-poster_-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Fragment-hits-for-BRD3-poster_-scaled.jpg\",\"width\":1811,\"height\":2560},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Advancing Novel Fragment Hits for Epigenetic Target BRD3: A Structural Approach\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Advancing Novel Fragment Hits for Epigenetic Target BRD3","description":"Discover compounds targeting BRD3 with Fragment-Based Drug Discovery (FBDD) - a promising approach for drug development in epigenetics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\/","og_locale":"fr_CA","og_type":"article","og_title":"Advancing Novel Fragment Hits for Epigenetic Target BRD3","og_description":"Discover compounds targeting BRD3 with Fragment-Based Drug Discovery (FBDD) - a promising approach for drug development in epigenetics.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\/","og_site_name":"Sygnature","article_modified_time":"2025-12-12T11:35:58+00:00","og_image":[{"width":724,"height":1024,"url":"http:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Fragment-hits-for-BRD3-poster_-724x1024.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\/","name":"Advancing Novel Fragment Hits for Epigenetic Target BRD3","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Fragment-hits-for-BRD3-poster_-scaled.jpg","datePublished":"2019-03-21T11:43:15+00:00","dateModified":"2025-12-12T11:35:58+00:00","description":"Discover compounds targeting BRD3 with Fragment-Based Drug Discovery (FBDD) - a promising approach for drug development in epigenetics.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/poster\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Fragment-hits-for-BRD3-poster_-scaled.jpg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Fragment-hits-for-BRD3-poster_-scaled.jpg","width":1811,"height":2560},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/structurally-enabled-progression-of-novel-fragment-hits-for-the-epigenetic-target-brd3-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Advancing Novel Fragment Hits for Epigenetic Target BRD3: A Structural Approach"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/3928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/poster"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/3928\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/2559"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=3928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=3928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}